Besides their potential utility to select high-risk or highly sensitive patients who might benefit most from CDK4/6 inhibitors in early breast cancer, gene expression signatures have recently been intended for measuring treatment activity as a new endpoint. This evidence concerns the gene CDK4 and breast carcinoma.